Campbell & CO Investment Adviser LLC Grows Stake in Becton Dickinson and Co (NYSE:BDX)

Campbell & CO Investment Adviser LLC raised its holdings in Becton Dickinson and Co (NYSE:BDX) by 397.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,073 shares of the medical instruments supplier’s stock after acquiring an additional 4,053 shares during the period. Becton Dickinson and comprises about 0.6% of Campbell & CO Investment Adviser LLC’s investment portfolio, making the stock its 11th largest holding. Campbell & CO Investment Adviser LLC’s holdings in Becton Dickinson and were worth $1,267,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of BDX. Harvest Group Wealth Management LLC acquired a new position in shares of Becton Dickinson and in the first quarter valued at approximately $25,000. Oregon Public Employees Retirement Fund grew its position in Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 6,545,502 shares in the last quarter. Pinnacle Financial Partners Inc. acquired a new stake in Becton Dickinson and during the first quarter worth approximately $29,000. RPG Investment Advisory LLC acquired a new stake in Becton Dickinson and during the first quarter worth approximately $32,000. Finally, Nalls Sherbakoff Group LLC acquired a new stake in Becton Dickinson and during the fourth quarter worth approximately $34,000. 84.54% of the stock is owned by hedge funds and other institutional investors.

NYSE:BDX traded up $2.86 during trading hours on Friday, hitting $252.01. 1,488,086 shares of the company were exchanged, compared to its average volume of 1,274,632. The company has a market cap of $67.57 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 1.84 and a beta of 1.12. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87. The business’s fifty day moving average is $236.09.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.02. The business had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. Becton Dickinson and’s revenue for the quarter was down .6% compared to the same quarter last year. During the same period last year, the company earned $2.65 EPS. On average, research analysts anticipate that Becton Dickinson and Co will post 11.69 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.22%. Becton Dickinson and’s payout ratio is currently 27.97%.

BDX has been the topic of a number of analyst reports. Morgan Stanley reduced their price target on Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating on the stock in a research report on Friday, May 10th. Barclays increased their price target on Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Raymond James reduced their price target on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research report on Tuesday, March 19th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, April 22nd. Finally, KeyCorp reissued an “overweight” rating and set a $262.00 price target (down previously from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $262.67.

In other Becton Dickinson and news, EVP Samrat S. Khichi sold 16,085 shares of the stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the sale, the executive vice president now directly owns 12,608 shares in the company, valued at approximately $2,958,845.44. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Betty D. Larson sold 1,700 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the sale, the executive vice president now owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,154 shares of company stock valued at $4,955,775. Company insiders own 0.12% of the company’s stock.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: What is a portfolio manager?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.